LEADER 04228oam 2200673 450 001 9910716097303321 005 20220513142814.0 035 $a(CKB)5470000002517127 035 $a(OCoLC)936068841 035 $a(EXLCZ)995470000002517127 100 $a20160126d2013 ua 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPatients with positive screening fecal occult blood tests $eevidence brief on the relationship between time delay to colonoscopy and colorectal cancer outcomes /$fKim Peterson [and three others] 210 1$aWashington, DC :$cDepartment of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service,$d2013. 215 $a1 online resource (i, 20 pages) $cillustrations 300 $a"Evidence-based synthesis program." 300 $a"April 2013." 320 $aIncludes bibliographical references (pages 13-15). 330 $a"The American Cancer Society estimates that colorectal cancer (CRC) will be the third most common cause of cancer death for both men and women in the U.S. in 2013. The natural history of the disease suggests that longer delays in CRC diagnosis will negatively influence stage at diagnosis and long-term survival. CRC may be diagnosed by screening asymptomatic patients or by evaluation of symptomatic patients. Previous studies investigating the influence of delays on survival or cancer stage at diagnosis have primarily focused on the evaluation of time from first symptom development in symptomatic patients and have demonstrated inconsistent results. For example, among 13 studies published between 1977 and 2006 included in a 2007 systematic review by Ramos and colleagues, 10 found no association between the symptom-to-diagnosis interval (SDI) and survival and the other three found that increased delays resulted in better chances of survival. As for the relationship between SDI and tumor stage, among 18 studies, 11 found no association, four found that shorter delays were associated with an earlier stage at diagnosis and three paradoxically found that a greater delay was associated with an earlier stage at diagnosis. As noted by Ramos et al., the SDI risk function is likely nonlinear and multifaceted, reflecting a complex interaction between tumor biology and location, the clinical course, patient behavior, and the functioning of the healthcare system, and the studies have varied in their methods for adjusting for these confounding factors. These findings highlight the importance of detecting colorectal cancer through screening, before symptoms appear"--Publisher's description. 517 $aPatients with positive screening fecal occult blood tests 606 $aFecal occult blood tests$zUnited States 606 $aColonoscopy$zUnited States 606 $aColon (Anatomy)$xCancer$zUnited States 606 $aOutcome assessment (Medical care)$zUnited States 606 $aColon (Anatomy)$xCancer$2fast 606 $aColonoscopy$2fast 606 $aFecal occult blood tests$2fast 606 $aOutcome assessment (Medical care)$2fast 607 $aUnited States$2fast 615 0$aFecal occult blood tests 615 0$aColonoscopy 615 0$aColon (Anatomy)$xCancer 615 0$aOutcome assessment (Medical care) 615 7$aColon (Anatomy)$xCancer. 615 7$aColonoscopy. 615 7$aFecal occult blood tests. 615 7$aOutcome assessment (Medical care) 700 $aPeterson$b Kim$01385536 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aPortland VA Medical Center.$bEvidence-based Synthesis Program Center. 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bMMU 801 1$bMMU 801 2$bOCLCQ 801 2$bGPO 801 2$bOCLCO 801 2$bOCLCF 801 2$bOCLCA 801 2$bOCLCQ 801 2$bOCLCO 801 2$bGPO 906 $aBOOK 912 $a9910716097303321 996 $aPatients with positive screening fecal occult blood tests$93451620 997 $aUNINA